The	O
objective	O
of	O
the	O
pilot	O
stage	O
of	O
the	O
study	O
was	O
a	O
preliminary	O
assessment	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
AVIFAVIR	O
,	O
and	O
to	O
select	O
the	O
optimal	O
dosing	O
regimen	O
for	O
further	O
evaluation	O
at	O
the	O
pivotal	O
stage	O
(	O
Phase	O
III	O
)	O
.	O

The	O
primary	O
efficacy	O
endpoint	O
at	O
the	O
pilot	O
stage	O
was	O
the	O
elimination	B-PrimaryOutcome
of	I-PrimaryOutcome
SARS	I-PrimaryOutcome
-	I-PrimaryOutcome
CoV	I-PrimaryOutcome
-	I-PrimaryOutcome
2	I-PrimaryOutcome
by	B-TimeFrame
Day	I-TimeFrame
10	I-TimeFrame
(	O
defined	B-OutcomeDefinition
as	I-OutcomeDefinition
two	I-OutcomeDefinition
negative	I-OutcomeDefinition
PCR	I-OutcomeDefinition
tests	I-OutcomeDefinition
with	I-OutcomeDefinition
at	I-OutcomeDefinition
least	I-OutcomeDefinition
a	I-OutcomeDefinition
24	I-OutcomeDefinition
-	I-OutcomeDefinition
hour	I-OutcomeDefinition
interval	I-OutcomeDefinition
)	O
.	O

Qualitative	O
Real	O
-	O
Time	O
RT	O
-	O
PCR	O
tests	O
were	O
performed	O
at	O
local	O
laboratories	O
of	O
the	O
clinical	O
sites	O
or	O
in	O
the	O
central	O
laboratory	O
of	O
Rospotrebnadzor	O
.	O

The	O
study	O
assessments	O
included	O
daily	B-OtherOutcome
vital	I-OtherOutcome
signs	I-OtherOutcome
,	O
SpO2	B-OtherOutcome
and	I-OtherOutcome
WHO	I-OtherOutcome
Ordinal	I-OtherOutcome
Scale	I-OtherOutcome
for	I-OtherOutcome
Clinical	I-OtherOutcome
Improvement	I-OtherOutcome
(	I-OtherOutcome
WHO	I-OtherOutcome
-	I-OtherOutcome
OSCI	I-OtherOutcome
)	I-OtherOutcome
;	O
PCR	B-OtherOutcome
for	I-OtherOutcome
SARS	I-OtherOutcome
-	I-OtherOutcome
CoV	I-OtherOutcome
-	I-OtherOutcome
2	I-OtherOutcome
detection	I-OtherOutcome
in	O
nasopharyngeal	O
and	O
/	O
or	O
oropharyngeal	O
swabs	O
at	O
baseline	O
and	O
on	B-TimeFrame
Days	I-TimeFrame
5	I-TimeFrame
,	I-TimeFrame
10	I-TimeFrame
,	I-TimeFrame
and	I-TimeFrame
15	I-TimeFrame
;	O
chest	B-OtherOutcome
computed	I-OtherOutcome
tomography	I-OtherOutcome
(	I-OtherOutcome
CT	I-OtherOutcome
)	I-OtherOutcome
scan	I-OtherOutcome
at	B-TimeFrame
baseline	I-TimeFrame
and	I-TimeFrame
on	I-TimeFrame
Day	I-TimeFrame
15	I-TimeFrame
;	O
physical	B-OtherOutcome
examination	I-OtherOutcome
,	O
complete	B-OtherOutcome
blood	I-OtherOutcome
count	I-OtherOutcome
,	O
biochemistry	B-OtherOutcome
,	O
C	B-OtherOutcome
-	I-OtherOutcome
reactive	I-OtherOutcome
protein	I-OtherOutcome
(	I-OtherOutcome
CRP	I-OtherOutcome
)	I-OtherOutcome
,	O
urinalysis	B-OtherOutcome
,	O
and	O
electrocardiogram	B-OtherOutcome
at	B-TimeFrame
baseline	I-TimeFrame
and	I-TimeFrame
on	I-TimeFrame
Days	I-TimeFrame
5	I-TimeFrame
and	I-TimeFrame
15	I-TimeFrame
.	O

If	O
not	O
discharged	O
from	O
the	O
hospital	O
earlier	O
,	O
the	O
patients	O
attended	O
follow	O
-	O
up	O
visits	O
on	O
Day	O
22	O
and	O
Day	O
29	O
.	O

All	O
patients	O
were	O
followed	O
until	O
Day	O
29	O
.	O

The	O
“	O
go	O
-	O
no	O
-	O
go	O
”	O
decision	O
to	O
start	O
the	O
pivotal	O
stage	O
of	O
the	O
study	O
was	O
based	O
on	O
the	O
exact	O
single	O
-	O
stage	O
Phase	O
II	O
assessment	O
at	O
one	O
-	O
sided	O
α	O
=	O
0	O
.	O
05	O
and	O
80	O
%	O
power	O
[	O
8	O
]	O
.	O

13	O
/	O
18	O
(	O
72	O
.	O
2	O
%	O
)	O
or	O
more	O
patients	O
would	O
have	O
been	O
sufficient	O
to	O
demonstrate	O
that	O
the	O
viral	O
clearance	O
in	O
80	O
%	O
of	O
patients	O
by	O
Day	O
10	O
was	O
plausible	O
,	O
and	O
that	O
the	O
response	O
was	O
greater	O
than	O
the	O
presumably	O
noneffective	O
level	O
of	O
50	O
%	O
.	O

The	O
secondary	O
endpoints	O
that	O
were	O
assessed	O
during	O
the	O
interim	O
analysis	O
were	O
the	O
rate	B-SecondaryOutcome
of	I-SecondaryOutcome
viral	I-SecondaryOutcome
clearance	I-SecondaryOutcome
by	B-TimeFrame
Day	I-TimeFrame
5	I-TimeFrame
,	O
time	B-SecondaryOutcome
to	I-SecondaryOutcome
normalization	I-SecondaryOutcome
of	I-SecondaryOutcome
clinical	I-SecondaryOutcome
symptoms	I-SecondaryOutcome
(	I-SecondaryOutcome
ie	I-SecondaryOutcome
,	I-SecondaryOutcome
body	I-SecondaryOutcome
temperature	I-SecondaryOutcome
)	I-SecondaryOutcome
,	O
changes	B-SecondaryOutcome
on	I-SecondaryOutcome
CT	I-SecondaryOutcome
scan	I-SecondaryOutcome
by	B-TimeFrame
Day	I-TimeFrame
15	I-TimeFrame
,	O
and	O
incidence	B-SecondaryOutcome
and	I-SecondaryOutcome
severity	I-SecondaryOutcome
of	I-SecondaryOutcome
adverse	I-SecondaryOutcome
events	I-SecondaryOutcome
related	I-SecondaryOutcome
to	I-SecondaryOutcome
the	I-SecondaryOutcome
study	I-SecondaryOutcome
drug	I-SecondaryOutcome
.	O

